Clinical Trial: An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Brief Summary: The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

Detailed Summary:
Sponsor: AstraZeneca

Current Primary Outcome: Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients by evaluation of the percentage of time that intragastric pH is >4.0 over a 24 hr period steady state

Original Primary Outcome: Same as current

Current Secondary Outcome: Compare pharmacodynamic efficacy of esomeprazole 40 mg & lansoprazole 30 mg bid in controlling intragastric pH in BE patients by evaluation of the % of time intragastric pH is >4.0 over 24 hr period at steady state

Original Secondary Outcome: Same as current

Information By: AstraZeneca

Dates:
Date Received: July 12, 2006
Date Started: January 2006
Date Completion:
Last Updated: March 25, 2009
Last Verified: March 2009